Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 5/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.42 |
| ▸ | DHFR | P00374 | 4/20 | 0.40 |
| ▸ | TYMS | P04818 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966212 | 0.89 | ERBB2 (0.53) | ERBB2HSP90AB1HSP90AA1DHFRTYMS | |
| SCHEMBL3744472 | 0.83 | HSP90AA1 (0.47) | ERBB2HSP90AB1HSP90AA1MAP4K4HSP90B1 | |
| SCHEMBL3111577 | 0.82 | HSP90B1 (0.50) | ERBB2HSP90AB1HSP90AA1DHFRTYMS | |
| SCHEMBL14467034 | 0.82 | ERBB2 (0.41) | ERBB2HSP90AB1HSP90AA1DHFRTYMS | |
| SCHEMBL13079975 | 0.81 | GAA (0.41) | ERBB2HSP90AB1HSP90AA1MAP4K4 | |
| SCHEMBL3126758 | 0.81 | HSP90AB1 (0.51) | ERBB2HSP90AB1HSP90AA1MAP4K4 | |
| SCHEMBL4339904 | 0.81 | ERBB2 (0.52) | ERBB2HSP90AB1HSP90AA1MAP4K4 | |
| SCHEMBL5038825 | 0.81 | ERBB2 (0.41) | ERBB2HSP90AB1HSP90AA1DHFR | |
| SCHEMBL3113829 | 0.81 | SCN8A (0.38) | DHFRMAP4K4 | |
| SCHEMBL3128953 | 0.79 | ERBB2 (0.40) | ERBB2HSP90AB1HSP90AA1DHFRTYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2009065035-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | VHL, CLN6, CFTR | ERBB2 802/4885HSP90AB1 501/4885HSP90AA1 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.